Biorelevant drug release of Metformin dosage forms using complementary in vitro tools by Box, Karl et al.
  https://doi.org/10.5920/bjpharm.2017.15  
Box et al (2017) BJPharm, 2(2), S9-10   S9 
www.bjpharm.hud.ac.uk 
A R T I C L E   I N F O S U M M A R Y 
Drug release from immediate release (IR) and extended release (ER) metformin 
products was investigated using the Dow Chemical Company’s FloVitroTM 
biorelevant dissolution instrument. This was complemented by using the Sirius SDi2 
(Surface Dissolution Imaging) platform to investigate mechanistic differences 
accounting for drug release. Level A IVIVC was demonstrated for metformin IR 
dosage forms, using FloVitroTM, whilst ER tablets demonstrated lower Cmax and 
Tmax using the same method. The SDi2 showed disintegration as the main release 
mechanism for IR tablets, whilst swelling and drug diffusion was observed for ER 
tablets. FloVitroTM and SDi2 technologies can be used to compare behaviour of 
formulations during dosage form selection 
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INTRODUCTION 
Data from traditional dissolution tests are notoriously 
difficult to correlate with in vivo outcomes. This is a 
key challenge in formulation development. In this 
study, two proprietary dissolution technologies were 
utilized to investigate the effect of formulation 
differences on drug release for immediate (IR) and 
extended (ER) release Metformin tablets. The Dow 
Chemical Company’s FloVitro™ biorelevant 
dissolution instrument was implemented to achieve 
level A IVIVC for the IR dosage form and for in vitro 
comparison of IR and ER tablets. Mechanistic 
differences accounting for drug release were 
investigated by real-time imaging using the Sirius 
SDi2. 
MATERIALS AND METHODS 
Experiments were carried out at 37oC using 500 mg 
Metformin HCl IR and ER tablets. Dilute HCl, pH 1.2 
and phosphate buffer, pH6.8 were used as dissolution 
media. 
The FloVitro™ system consists of three chambers 
representing gastric, intestinal and systemic 
absorption compartments. FloVitro™ dissolution was 
studied using flow rates of 1 and 2 mL/min for HCl 
and phosphate buffer, respectively. 
FloVitro™ drug concentration was measured over 16 
or 24 hours using inline spectrophotometry (247 nm). 
The results were compared to in-vivo data from a 
previous clinical trial (Idkaidek, 2011). 
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Sirius SDi2 experiments were performed using a USP 
IV type flow cell at a flow rate of 8.2 mL/min. The 
SDi2 is designed for whole dosage imaging of tablets 
or capsules. Absorbance data at 255 and 520 nm 
wavelengths were collected over 3 hours for the 
Metformin IR tablets and for 10 hours for the 
Metformin ER tablets. The dual-wavelength 
capability allows discrimination between the 
dissolved API, the dosage form and excipients. 
RESULTS AND DISCUSSION 
FloVitro™ results for the IR dosage form are shown in 
Figure 1 (top panel). Superimposed is the scaled in- 
vivo data. Level A IVIVC was achieved for IR 
Metformin with R2 = 0.945 (Figure 1B). 
Results for an ER dosage form using the same method 
demonstrated lower in vitro cmax and later tmax (Table 
1, and Figure 1A). 
 
 
Figure 1[A] FloVitro™ concentration profile (IR and ER 
Metformin) with superimposed scaled in vivo data.  
[B] IVIVC plot showing Level A correlation. 
Mechanistic details accounting for the observed 
differences were obtained using the Sirius SDi2: The 
IR tablet disintegrated, leading to rapid onset of drug 
release. The ER tablet swelled in acid and only after a 
transition into pH6.8 phosphate buffer did the drug 
diffuse gradually into solution from the hydrogel 
matrix, while the dosage form remained intact (Figure 
2). 
Table 1. Mass dissolved and IDR of free base and salts. 
 
Dosage Form Cmax (ng/mL) tmax (h) 
IR formulation 479 3 
ER formulation 283 6 
 
 
Figure 2. Sirius SDi2 images at 255 nm and 520 nm 
detection wavelengths for ER metformin tablets. Red 
zones indicate quantification region. 
CONCLUSIONS 
FloVitro™ and the Sirius SDi2 are novel, 
complementary techniques which provide detailed in 
vitro discrimination between IR and ER dosages of 
metformin. These technologies may also be used to 
rank comparative performance of formulations of 
other drugs, providing invaluable information to 
assist dosage form selection. 
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